Technical Analysis for ABEO - Abeona Therapeutics Inc.

Grade Last Price % Change Price Change
F 1.5 -6.25% -0.10
ABEO closed down 6.25 percent on Thursday, April 15, 2021, on 29 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical ABEO trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Stochastic Buy Signal Bullish -6.25%
Outside Day Range Expansion -6.25%
Wide Bands Range Expansion -6.25%
Oversold Stochastic Weakness -6.25%
Narrow Range Bar Range Contraction -2.60%
NR7 Range Contraction -2.60%
Wide Bands Range Expansion -2.60%
Down 3 Days in a Row Weakness -2.60%
Older End-of-Day Signals for ABEO ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 5% about 13 hours ago
Fell Below Previous Day's Low about 13 hours ago
Down 3% about 15 hours ago
60 Minute Opening Range Breakdown about 15 hours ago
Down 2 % about 15 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Abeona Therapeutics Inc. Description

Abeona Therapeutics, Inc., formerly PlasmaTech Biopharmaceuticals, Inc., is focused on developing and delivering gene therapy and plasma-based products for severe and rare diseases. The Company's lead program includes adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome (MPS IIIA and IIIB). Its product pipeline includes ABO-101 (sc AAV9 NAGLU), which is used for the treatment of MPS III B; ABO-102 (sc AAV9 SGSH), which is used for the treatment of MPS III A; ABO-201 (sc AAV9 CLN3), which is used for the treatment of Juvenile Batten Disease (JBD); ABO-301 (AAV LK19 FANCC), which is used for the treatment of Fanconi Anemia (FA), and clustered, regularly interspaced short palindromic repeats/CRISPR associated protein 9 (CRISPR/Cas9) gene editing, which is used for treatment of other rare blood diseases. The Company offers two platforms: Salt Diafiltration (SDF) Process and Polymer Hydrogel Technology (PHT).


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biology Emerging Technologies Rare Diseases Genetics Molecular Biology Gene Therapy Anemia Genetic Engineering Biopharmaceuticals CRISPR Genome Editing Adeno Associated Virus Cas9 Severe And Rare Diseases Blood Diseases Fanconi Anemia

Is ABEO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.7899
52 Week Low 0.99
Average Volume 4,166,423
200-Day Moving Average 2.01
50-Day Moving Average 2.20
20-Day Moving Average 1.79
10-Day Moving Average 1.65
Average True Range 0.16
ADX 22.12
+DI 14.97
-DI 24.74
Chandelier Exit (Long, 3 ATRs ) 1.90
Chandelier Exit (Short, 3 ATRs ) 1.98
Upper Bollinger Band 2.16
Lower Bollinger Band 1.42
Percent B (%b) 0.11
BandWidth 41.58
MACD Line -0.17
MACD Signal Line -0.15
MACD Histogram -0.0165
Fundamentals Value
Market Cap 147.79 Million
Num Shares 98.5 Million
EPS -1.59
Price-to-Earnings (P/E) Ratio -0.95
Price-to-Sales 18.35
Price-to-Book 1.30
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.71
Resistance 3 (R3) 1.73 1.69 1.68
Resistance 2 (R2) 1.69 1.63 1.68 1.66
Resistance 1 (R1) 1.59 1.60 1.57 1.57 1.65
Pivot Point 1.55 1.55 1.54 1.54 1.55
Support 1 (S1) 1.45 1.49 1.43 1.43 1.35
Support 2 (S2) 1.41 1.46 1.40 1.34
Support 3 (S3) 1.31 1.41 1.33
Support 4 (S4) 1.29